Search
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Categories: Compounds used in a research, industrial, or household settingInfluenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15702ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Tetra Injektionssuspension in einer FertigspritzeElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Poliovirus type 1 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10795ApprovedInvestigationalPoliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEPoliovirus type 3 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10797ApprovedInvestigationalPoliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGECapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalmetastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … Dihydroergotamine is used as an abortive therapy for migraines.
Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamideAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnAminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Synonyms: N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acidBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalIt has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.
Categories: Antivirals used in combination for the treatment of HIV infectionsNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.